Reversal of 5-flourouracil resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells

Zhi-Wei Yu, Peng Zhao, Ming Liu, Xin-Shu Dong, Ji Tao, Xue-Qin Yao, Xin-Hua Yin, Yu Li, Song-Bin Fu

Abstract
AIM: To observe the reversal effects of wide-type p53 gene on multi-drug resistance to 5-FU (LOVO/5-FU).

METHODS: After treatment with Ad-p53, LOVO/5-FU sensitivity to 5-FU was investigated using tetrazolium dye assay. Multidrug resistance gene-1 (MDR1) gene expression was assayed by semi-quantitative reverse transcription-polymerase chain reaction and the expression of p53 protein was examined by Western blotting.

RESULTS: The reversal activity after treatment with wide-type p53 gene was increased up to 4.982 fold at 48 h. The expression of MDR1 gene decreased significantly after treatment with wide-type p53 gene, and the expression of p53 protein lasted for about 5 d, with a peak at 48 h, and began to decrease at 72 h.

CONCLUSION: Wide-type p53 gene has a remarkable reversal activity for the high expression of MDR1 gene in colorectal cancers. The reversal effects seem to be in a time dependent manner. It might have good prospects in clinical application.

INTRODUCTION
Resistance to cytotoxic agents is the major cause of failure of medical treatment of human cancer and it is known that tumor cells can become resistant to anticancer drugs by a variety of different mechanisms[1]. MDR (multidrug-resistance) is a form of drug resistance characterized by decreased cellular sensitivity to a broad range of chemotherapeutic agents and due significantly to the over expression of MDR1 mRNA and its product P-gp[2,3]. As an integral membrane protein, the M, 170 000 P-gp is thought to be an energy-dependent membrane pump involved in the excretion of toxins in normal cells[4]. Elevated expression of P-gp in malignant cells results in increased efflux and therefore reduced intracellular accumulation of cytotoxic agents, such as 5-FU, anthracyclines, Vinca alkaloids, and epipodophyllotoxins, but is not cross-resistant to alkylating agents, antimetabolites, and cisplatin. This decrease is considered as the basic mechanism of the MDR phenomenon[4-7]. While a number of pharmacological agents have been shown to partially reverse MDR in vitro[8], there remains a need to identify more potent, more specific, and less toxic chemosensitizers for clinical use.

Inactivity of p53 gene by missense mutation or deletion is the most common genetic alteration in human cancers[9]. The loss of p53 function has been reported to enhance cellular resistance to a variety of chemotherapeutic agents[10-13]. Our preliminary experiments[14] also showed that there was a strong relationship between the MDR1 gene expression and mutated p53 gene in colorectal cancers.

Thus, in light of the fact that MDR1 is over-expressed in colorectal cancer that often lacks a functional p53[15,16], we ask whether p53 plays a role in the control of MDR1 gene. Therefore, we sought to determine whether the introduction of the wild- type p53 gene in LOVO/5-FU cells by an adenoviral vector could increase the sensitivity of cells to a DNA cross-linking agent 5-FU in vitro and in vivo.

MATERIALS AND METHODS
Cell culture
LoVo cells were derived from a human colon adenocarcinoma. 5-FU-resistant LoVo sub-line (LoVo/5-FU) was obtained from the LoVo cell line by selection with 5-FU[15], and maintained in medium containing 5 ng/mL 5-FU as described previously. LoVo/5-FU cells were kindly provided by Dr. Xue-Qing Yao. Monolayer cultures of LoVo and LoVo/5-FU were maintained in RPMI 1640 medium supplemented with 150 g/L heat-inactivated fetal calf serum (Sigma Chemical Co), 10 mL/L of a 200 mmol/L glutamine solution, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10 g/L vitamin solution for minimum essential Eagle’s medium purchased from GIBICO-BRL (Gaithersburg, MD). Cells lines grown in the presence of agents were passed in drug-free medium 2 to 3 times prior to use. All cells were grown at 37 °C in a humidified atmosphere of 50 mL/L CO2 and 950 mL/L air.

Adenovirus vectors
Construction and identification of Ad-p53 and Ad-LacZ were finished and kindly provide by Dr. Xin-Hua Yin. Briefly, recombinant p53 adenovirus, Ad5CMV-p53 containing cytomegalovirus promoter, wild-type p53 cDNA, and SV40...
early lopyadenylation signal in a minigene cassette was inserted into the E1-deletion region of modified Ad5. p53 shuttle vector and recombinant plasmid pJM 17 were cotransfected into 293 cells (Ad-transformed human embryonic kidney cells) by a liposome-mediated technique. The culture supernatant of 293 cells showing the complete cytopathic effect was collected and used for subsequent infections. Control Ad-LacZ virus was generated in a similar manner. Viral titers were determined by plaque forming activity in 293 cells. Concentrated virus was generated in a similar manner. Viral titers were determined by plaque forming activity in 293 cells. Concentrated virus was dialyzed, aliquoted, and stored at -80°C.

Comparison of MDR1 mRNA expression in parental and drug-resistant LoVo cells by RT-PCR

Drug sensitivity testing

Chemosensitizers in the various cell lines were determined by using the tetrazolium-based colorimetric assay (MTT [i.e., 3-(4,5-dimethyl-2-thiazoly1)-2-m 5-dipheny1-2H-tetrazolium bromide] assay). Cells (LoVo/5-FU/Ad-p53 cells, LoVo/5-FU cells, LoVo cells;) were seeded in a 96-well microtiter plate at a density of 1x10^4 cells/well and each well contained 200 μL medium. Cells were exposed 24 h after plating to various concentrations of 5-FU for 4 h. After treatment, medium was removed and replaced with 200 μL of drug-free medium. Plates were incubated for further 72 h. At this time, 15 μL of MTT (4 mg/mL) solution was added to each well. After a 4-h incubation at 37°C, the cellular supernatant was gently aspirated, and insoluble formazan crystals were dissolved by adding 180 μL 1 000 g/L DMSO (dimethyl sulfoxide) to each well, then the plates were shaken for about 10 min. The absorbance of each well was determined by a spectrophotometer at a wavelength of 570 nm with a microculture plate reader. Inhibition of cell growth was determined as a percentage of absorbance of vehicle-treated control cultures. IC₅₀ was the concentration of drugs that reduced staining (ΔA₅₇₀) to 50% of vehicle-treated controls.

The effect of chemosensitizers on drug resistance was studied by exposing cells to a range of concentrations of cytotoxic drugs in the absence or presence of concentrations of chemosensitizers. Dose-response curves were corrected for the inhibition of cell growth caused by chemosensitizers alone, and the “fold reversal” of MDR for 5-FU plus chemosensitizer combination was calculated as follows:

\[
\text{Fold reversal} = \frac{\text{IC}_{50,\text{drug alone}}}{\text{IC}_{50,\text{drug-chemosensitizer}}}
\]

Western blot analysis of wild-type p53 expression

Cells infected with the indicated adenovirus and MOI were grown to about 80% confluence in 10-cm plates. After washed with PBS, cells were scraped from the plate, washed once with ice-cold PBS containing 1 mMol/L phenylmethylsulfonyl fluoride, and centrifuged at 1 000 r/min for 4 min. The cell pellet was resuspended in ice-cold radioimmunoprecipitation assay buffer (1% NP40, 0.5% sodium deoxycholate, and 1 g/L SDS, 10 μg/mL aprotinin, 10 μg/mL leupeptin and 1 μg/mL pepstatin) and sonicated. After centrifugation at 12 000 g at 4°C for 20 min, the resulting supernatant was harvested as the total cell lysate. The protein was aliquoted and stored at -70°C until use. Protein samples were electrophoresed through a 125 g/L polyacrylamide gel containing 1 g/L SDS and the gel was run at 30 mA for 3 h. Separated proteins were transferred onto nitrocellulose paper by electroblotting. After blocked with 50 mL/L blocking reagent, the nitrocellulose membrane was probed with a monoclonal antibody against human wild-type p53 from Oncogene Science. Detection was accomplished using ECL western blotting detection reagents from Amersham Pharmacia Corp.

RESULTS

Sensitivity of LoVo and LoVo/5-FU to 5-flurouracil

The sensitivity of LoVo and LoVo/5-FU cells to 5-flurouracil was evaluated using the MTT assay as shown in Table 1. Previous studies using MTT assays have shown that the LoVo/5-FU cell line is 8.988-fold more resistant to 5-flurouracil than parental LoVo cells. We found the two cell lines showed differences in sensitivity to 5-flurouracil, too. The concentration inducing 50% inhibition of cell proliferation for 5-Flurouracil was 0.82 μg/mL for the parental line and 7.37 μg/mL for the LoVo/5-FU cells.

Effect of wtp53 gene on cell growth in LoVo/5-FU cells

Figure 1 showed the effect of wild-type p53 on the LoVo/5-FU cells. It suggested that the dose of Ad-p53 for experiment didn’t affect the growth rate of LoVo/5-FU cells during the six days after transfection.
**Figure 1** Effect of wild-type p53 on the growth rate of LoVo/5-FU cells.

**Effect of wild-type p53 on LoVo/5-FU cells sensitivity to 5-flourouracil**

The effect of wild-type p53 on 5-flourouracil sensitivity was examined using the MTT assay. A dose of 8.17×10^6 pfu/mL Ad-p53 was chosen as the dose to modulate 5-flourouracil sensitivity. For this study, cells were treated with wild-type p53 for 48 h, 5-flourouracil was then added to the final concentration of 0.25 to 15 µg/mL for 3 h, and then the medium was removed and replaced with a fresh medium without drugs and the incubation was continued. Cell growth was determined after an addition for 72 h. Treatment with wild-type p53 appeared to decrease the resistance of LoVo/5-FU cells to 5-flourouracil (Table 1).

**Table 1** Effect of wild-type p53 on LoVo/5-FU sensitivity to 5-flourouracil

| Cell lines                        | IC50 (µg/mL) | Resistant time | Reverse time |
|-----------------------------------|--------------|----------------|--------------|
| LoVo cells                        | 0.82         |                |              |
| LoVo/5-FU cells                   | 7.37         | 8.988          |              |
| LoVo/5-FU cells+wild-type p53      | 1.48b        | 1.804          | 4.982        |

*P <0.01 compared with LoVo/5-FU cell control group.

**Expression of wild-type p53 protein in cell lines**

The X-gal staining suggested that the dilution of 1:20 for Ad-p53 could make about more than 80% cells infected successfully. LoVo/5-FU was transduced *in vitro* with the human wild-type p53 cDNA by exposing to Ad-p53 (1:20). To make sure that the constructed p53 expression vector, Ad-p53, efficiently expressed functional wild-type p53, we determined its protein expression and transactivating function. Western blot analysis showed a higher level of wild-type p53 protein expression as early as 48 h after infection with Ad-p53, and which lasted for 5 d, then decreased significantly on the sixth day. But no wild-type p53 was detected in parental (uninfected) cells or control cells infected with Ad-LacZ (data not shown), suggesting that the transfer and expression of p53 by Ad-p53 were highly efficient (Figure 2).

**Figure 2** Western blot analysis of wild-type p53 in LoVo/5-FU cell line and LoVo/5-FU cells transiently transfected with p53 expression vector (Ad-p53). Lane 1: LoVo/5-FU cell line. Lanes 2, 3, 4, 5, 6: LoVo/5-FU cells transiently transfected with Ad-p53 for 2, 3, 4, 5, 6 d accordingly. Levels of wild-type p53 protein (lanes 2-6) were determined by Western-blot analysis with an antibody which could detect wild-type forms of p53 protein.

**Expression of wild-type p53 suppressed endogenous MDR1 gene expression**

We asked whether wild-type p53 expression could indeed inhibit endogenous MDR1 gene expression in LoVo/5-FU cells. Successful generation of cell lines constantly expressing wild-type p53 was tested in human LoVo/5-FU cells transfected with Ad-p53 as above, and these cells constantly maintained wild-type p53 for about 6 d and provided a valuable reagent for studying drug sensitivity. As seen in Figure 2, vector-transfected LoVo/5-FU cells expressing wild-type p53, had a lower MDR1 mRNA expression than LoVo/5-FU cells without wild-type p53 expression, as determined by RT-PCR. There was a decrease in MDR1 transcripts compared with the empty vector-transfected cell line, suggesting that constitutive expression of p53 could inhibit endogenous MDR1 transcription in LoVo/5-FU cells, and this suppression showed a time-dependent mode Figure 3, 4 and Tables 2, 3.

**Figure 3** Results of RT-PCR for expression of MDR1 mRNAs in p53-null and wild-type p53 expressing LoVo/5-FU cells. M: marker; Lanes 1 and 2: results of untransfected LoVo/5-FU cells; Lanes 3 and 4: results of transfected LoVo/5-FU cells.

**Figure 4** Results of RT-PCR for expression of MDR1 mRNAs of transfected LoVo/5-FU cells at different time. M: marker; Lanes 1, 2, 3, 4, 5: the cells transfected with Ad-p53 for 2, 3, 4, 5, 6 d accordingly.

**Table 2** MDR1 expression in different cell lines

| Lane | MDR1/β-actin |
|------|--------------|
| 1    | 1.26         |
| 2    | 1.19         |
| 3    | 0.42         |
| 4    | 0.33         |

**Table 3** MDR1 expression of LoVo/5-FU cells on different day after dealing with Ad-p53

| Time/d | MDR1/β-actin |
|--------|--------------|
| 2      | 1.22         |
| 3      | 1.24         |
| 4      | 1.06         |
| 5      | 0.86         |
| 6      | 0.42         |

**DISCUSSION**

Tumor cell resistance to chemotherapeutic drugs represents a major problem in clinical oncology; patients with colorectal...
cancer are generally unresponsive to chemotherapy. The goal of our current cancer research was to find ways to improve the efficacy of gene replacement therapy for cancer by investigating interactions between the gene products and chemotherapeutic drugs.

Resistance to cytotoxic agents is the major cause of failure of medical treatment of human cancer and it is known that tumor cells could become resistant to anticancer drugs by a variety of mechanisms[1]. In numerous in vitro models, this resistance has been shown to be mediated by MDR1 gene, whose product P-gp is thought to be an energy-dependent membrane pump involved in the excretion of toxins in normal cells. Elevated expression of P-gp in malignant cells could result in increased efflux and therefore reduced intracellular accumulation of cytotoxic agents. This decrease has been considered as the basic mechanism of the MDR phenomenon[2,3].

LoVo/5-FU cells were selected from the LoVo parental cell line through culture in the presence of 5-fluorouracil and were resistant to 5-FU which was toxic to LoVo parental cells. LoVo/5-FU cells had cross-resistance to the drugs comprising the classical MDR phenotype[15]. In this study, we found the resistance subline overexpressed MDR1 mRNA and no wild-type p53 protein was expressed.

An adenovirus system has potential advantages for gene delivery in vivo, such as easy production of high titer virus, high infection efficiency, and infectivity for many types of cells[16-18]. The stability and duration of the expression of introduced gene are still controversial. For chemotherapy, the expression levels and high infectivity may be more significant than the duration of expression because drugs can kill infected cells within several days. In our model, the expression of wild-type p53 gene was driven independently by the cytomegalovirus promoter contained in an Ad-p53 vector. The expression of wild-type p53 protein by Ad-p53 peaked after 48 h and decreased to a low level by the sixth day. This suggests that a transiently high level of wild-type p53 expression is sufficient to initiate the cytotoxic program in cancer cells.

We found that pretreatment of LoVo/5-FU cells with Ad-p53 was capable of restoring cell sensitivity to 5-fluorouracil. In the parental cell line, however, Ad-p53 did not potentiate 5-fluorouracil toxicity. The functional reversal of MDR by Ad-p53 in LoVo/5-FU cells appeared to be mediated by changes of the MDR1 gene expression.

Several agents have been described to affect MDR1 gene expression or the MDR phenotype in human or rodent cells, such as the Ca2+ channel blocker, verapamil, calmodulin inhibitor, trifluoperazine, which have been shown to reverse the MDR phenotype in vitro through direct competition with drugs for P-gp binding in the absence of changes in P-gp expression. Treatment with these agents could result in increased intracellular concentrations of cytotoxic drugs, which are thus a final common pathway in the reversal of the multidrug-resistant phenotype. They are presently used in clinical trials to patients with drug refractory tumors. However, they could induce significant cardiotoxicity, thus which limiting their clinical usefulness[19,20]. The Ad-p53 concentrations reported here are active in vivo in the absence of significant toxicity.

Wild-type p53, a 53,000 nuclear phosphoprotein involved in the control of cell growth and apoptosis is the most commonly altered gene in human tumors[21]. Its role as a tumor suppressor has been well documented as its inactivation was strongly correlated with human cancer[22-23]. p53 protein had different domains for DNA binding, transactivation, and tetramerization function[24,25]. After binding to consensus for DNA sequences, p53 could positively regulate the expression of downstream effector genes, including Gadd45, p21 (WAF1/CIP1)[26] and mouse muscle creatine kinase[27]. In addition, wild-type p53 could also negatively regulate a variety of genes that lack a p53 consensus binding site, including DNA topoisomerase II[28], MDR1[29-32], c-fos[33], and other viral and cellular promoters. It has been suggested that transcriptional repression by p53 could result from its direct interactions with transcription factors, such as TATA-binding protein[34,35], Sp1[16,37] and CCAAT-binding factor[28]. Taken together, these observations strongly imply that p53 acts directly with the transcription machinery to modulate MDR1 transcription.

Many tumors have no functional p53, and others express high levels of MDR1. Whether there is a direct connection has remained to be determined[3]. However, our results suggested that restoration of wild-type p53 in tumor cells could overcome the uncontrolled up-regulation of MDR1 gene expression, and could add to the beneficial effect of wild-type p53 gene therapy that would restore cell growth inhibition and apoptosis pathway to facilitate drug-induced cell killing.

A variety of treatment protocols, including surgery, chemotherapy, and radiotherapy, have been tried for human colorectal cancer, but the long-term survival rate remains unsatisfactory. The combination therapy we present here might be effective as an adjuvant treatment to prevent local recurrence following primary tumor resection or as a treatment that could be given by intralesional injections in drug-resistant primary, metastatic, or locally recurrent colorectal cancer. Protocols are being developed to explore these clinical applications.

REFERENCES

1. Zhu XH, Li JY, Xia XM, Zhu MQ, Geng MJ, Chen L, Zhang JQ. Multidrug resistance mechanisms in cell line HL-60 VCR. Aiheng 2002; 21: 1310-1313
2. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94: 15-21
3. Tsuruo T. Molecular cancer therapeutics: recent progress and targets in drug resistance. Intern Med 2003; 42: 237-243
4. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295-1310
5. Johnstone RW, Ruelff AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000; 25: 526-532
6. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997; 53: 587-596
7. Abu-Qare AW, Elmasry E, Abou-Dovia MB. A role for P-glycoprotein in environmental toxicology. J Toxicol Environ Health B Crit Rev 2003; 6: 279-288
8. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-165
9. Tullo A, D’Erchia AM, Sbisa E. Methods for screening tumors for p53 status and therapeutic exploitation. Expert Rev Mol Diagn 2003; 3: 289-301
10. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninon IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 2002; 99: 389-394
11. Yatolostskaya EM, DeHaan RD, Persons DL. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 2001; 283: 732-737
12. Yuan R, Meng Q, Hu H, Goldberg ID, Rosen EM, Fan S. P53-independent downregulation of p73 in human cancer cells treated with Adriamycin. Cancer Chemother Pharmacol 2003; 47: 161-169
13. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56: 802-806
14. Yu ZW, Dong XS, Wang XH. The relationship between the mdr1 gene expression and mutations of p53 gene and ras gene in colorectal cancer. Chin J Oncol 2002; 24: 480
Yu ZW et al. Reversal of 5-flourouracil resistance by transfer of wild-type p53 gene in LoVo/5-FU cells 1993

15 Yao XQ, Qing SH, Yang Y. Establishment of multidrug-resistant human colorectal cancer cell line LoVo/5-FU: a preliminary study of biological characterization. J First Mil Med Univ 2001; 21: 19-21

16 Xu ZL, Mizuguchi H, Mayumi T, Hayakawa T. Regulated gene expression from adenovirus vectors: a systematic comparison of various inducible systems. Gene 2003; 309: 145-151

17 Mohr L, Geissler M. Gene therapy: new developments. Schweiz Rundsch Med Prax 2002; 91: 2227-2225

18 Park J, Ries J, Gelse K, Kloss F, von der Mark K, Wittfang J, Neukam FW, Schneider H. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 2003; 10: 1089-1098

19 Durie BG, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988; 68: 203-206

20 Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913-917

21 Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526

22 Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wide-type p53. Science 1990; 249: 912-915

23 Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type p53 and mutant p53. FASEB J 1993; 7: 855-865

24 Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355

25 Wolcke RJ, Reimann M, Klumpp M, Gohler T, Kim E, Deppert W. Analysis of p53 “latency” and “activation” by fluorescence correlation spectroscopy: Evidence for different modes of high affinity DNA binding. J Biol Chem 2003; 278: 32587-32595

26 Sowa Y, Sakai T. Gene-regulating chemoprevention against cancer–as a model for “molecular-targeting prevention” of cancer. Nippon Eiseigaku Zasshi 2003; 58: 267-274

27 Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 1992; 6: 1143-1152

28 Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol 1997; 17: 389-397

29 Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-462

30 Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type p53 and mutant p53. Oncogene 1993; 8: 1529-1535

31 Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. P53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 1997; 94: 11037-11042

32 Bush JA, Li G. Regulation of the Mdr1 isoforms in a p53-deficient mouse model. Carcinogenesis 2002; 23: 1603-1607

33 Eikeles A, Juven-Gershon T, Israeli D, Wilder S, Zalzenstein A, Oren M. The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor. Mol Cell Biol 1999; 19: 2594-2600

34 Seto E, Ushova A, Zambetti GP, Momand J, Horikoshi N, Weismann R, Levine AJ, Shenk T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A 1992; 89: 12028-12032

35 Huang H, Kaku S, Knights C, Park B, Clifford J, Kulesz-Martin M. Repression of transcription and interference with DNA binding of TATA-binding protein by C-terminal alternatively spliced p53. Exp Cell Res 2002; 279: 248-259

36 Borellini F, Glazer RI. Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem 1993; 268: 7923-7928

37 Liedtke C, Groger N, Manns MP, Trautwein C. The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J Biol Chem 2003; 278: 27593-27604

38 Galmarini CM, Kamath K, Variier-Viornery A, Hervieux V, Peiller E, Falette N, Puisieux A, Ann Jordan M, Dumontet C. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 2003; 88: 1793-1799

Edited by Wang XL and Xu FM